Usage and synthesis methods of calcium hydroxybenzenesulfonate pharmacological effects 1. Calcium hydroxybenzenesulfonate has the ability to inhibit the high permeability of vasoactive substances (histamine, 5-hydroxytryptamine, bradykinin, hyaluronidase, prostaglandins) on microvessels, reduce vascular intimal damage, improve the biosynthesis of basement membrane collagen, and also improve the permeability of capillary walls, enhance the flexibility of red blood cells, reduce blood viscosity, and improve lymphatic reflux, This reduces the pathological high permeability of microvascular walls. 2. Calcium hydroxybenzenesulfonate can reduce the levels of fibrinogen and globulin, reduce the high aggregation of red blood cells, activate fibrinolytic activity, increase the solubility of blood fibrin, and thus reduce blood viscosity. Reduce the synthesis and release of platelet aggregation factors, inhibit various aggregation factors, cause aggregation reactions and spontaneous platelet aggregation, reduce platelet activity, and prevent thrombosis. Its effect is dose-dependent. 3. For microvascular lesions, calcium dobesilate can increase the caliber of arterioles and venules, increase the number of open capillaries, significantly accelerate blood flow velocity, and significantly improve microcirculation. Eliminate or alleviate edema, capillary bleeding, lower limb heaviness, and stress. 4. Calcium hydroxybenzenesulfonate significantly reduces the content of sorbitol, blocks the pathway of sugar to sorbitol, and inhibits the dysfunction caused by the increase of sorbitol in blood cells. The occurrence of adverse reactions of calcium hydroxybenzenesulfonate is rare, with the main adverse reactions being fever (26%), gastrointestinal discomfort (12.5%), skin reactions (8.2% Chemicalbook), joint pain (4.3%), and neutropenia (4.3%). No deaths have been reported. Pharmacokinetic administration of 500mg calcium dobesilate orally resulted in a blood concentration level of 6% between the 3rd and 10th hours μ Above g/ml, after 6 hours (maximum T), the blood drug concentration (maximum C) reaches its maximum value, with an average of 8 μ G/ml. The blood drug concentration after 24 hours of medication is approximately 3 μ G/ml. The protein binding rate is between 20% and 25%. Trace amounts are present in breast milk. Calcium dobesilate does not enter the enterohepatic circulation and is mainly excreted in its original form, with only 10% excreted as metabolites. Within 24 hours after medication, approximately 50% of the oral dose is excreted from urine and approximately 50% is excreted from feces. The plasma half-life is around 5 hours. Overview: Calcium dobesilate (trade names include Daosheng Ming, Dobeside, Andomin, Haochang, etc.), chemical name 2, 5-dihydroxybenzenesulfonate calcium monohydrate. It is a vasodilator that selectively acts on the walls of capillaries. It can not only adjust and improve the permeability and brittleness of capillary wall, but also inhibit bradykinin and other active substances. It is mainly used to treat capillary diseases caused by various reasons, such as diabetes retinopathy, varicose veins, phlebitis, leg spasm, phlegmatic dermatitis, etc. This product has high bioavailability, low toxicity, and high therapeutic index, making it an ideal drug for treating capillary diseases. White crystalline powder with chemical properties. Use as a microvascular nutrient